BRIEF-Ziopharm Oncology Reports Q4 And Full Year 2020 Financial Results

Reuters

Feb 26, 2021

Feb 25 (Reuters) - ZIOPHARM Oncology Inc :

* ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $0.11

* Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA

* HEIDI HAGEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER REPLACING DR. LAURENCE COOPER; SEARCH FOR PERMANENT CEO INITIATED

* NET LOSS FOR Q4 OF 2020, WAS $22.8 MILLION, OR $0.11 PER SHARE

* CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2020 WERE $115.1 MILLION

* CASH POSITION IS SUFFICIENT TO FUND COMPANY OPERATIONS INTO Q2 OF 2022

* RECEIVED IND CLEARANCE BY U.S. FDA FOR CO'S TCR-T TRIAL UTILIZING SIX "HOTSPOT" TCRS FROM ITS LIBRARY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2114759326"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2114759326\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2114759326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-02-26 07:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2114759326","market":"us","top_or_hot":-1,"title":"BRIEF-Ziopharm Oncology Reports Q4 And Full Year 2020 Financial Results","media":"Reuters","content":"<html><body><p>Feb 25 (Reuters) - <a href=\"https://laohu8.com/S/ZIOP\">ZIOPHARM Oncology Inc</a>   :</p><p>   * ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS</p><p>   * Q4 LOSS PER SHARE $0.11</p><p>   * Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA</p><p>   * HEIDI HAGEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER REPLACING DR. LAURENCE COOPER; SEARCH FOR PERMANENT CEO INITIATED</p><p>   * NET LOSS FOR Q4 OF 2020, WAS $22.8 MILLION, OR $0.11 PER SHARE</p><p>   * CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2020 WERE $115.1 MILLION</p><p>   * CASH POSITION IS SUFFICIENT TO FUND COMPANY OPERATIONS INTO Q2 OF 2022</p><p>   * RECEIVED IND CLEARANCE BY U.S. FDA FOR CO'S TCR-T TRIAL UTILIZING SIX \"HOTSPOT\" TCRS FROM ITS LIBRARY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ziopharm Oncology Reports Q4 And Full Year 2020 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ziopharm Oncology Reports Q4 And Full Year 2020 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-26 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 25 (Reuters) - <a href=\"https://laohu8.com/S/ZIOP\">ZIOPHARM Oncology Inc</a>   :</p><p>   * ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS</p><p>   * Q4 LOSS PER SHARE $0.11</p><p>   * Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA</p><p>   * HEIDI HAGEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER REPLACING DR. LAURENCE COOPER; SEARCH FOR PERMANENT CEO INITIATED</p><p>   * NET LOSS FOR Q4 OF 2020, WAS $22.8 MILLION, OR $0.11 PER SHARE</p><p>   * CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2020 WERE $115.1 MILLION</p><p>   * CASH POSITION IS SUFFICIENT TO FUND COMPANY OPERATIONS INTO Q2 OF 2022</p><p>   * RECEIVED IND CLEARANCE BY U.S. FDA FOR CO'S TCR-T TRIAL UTILIZING SIX \"HOTSPOT\" TCRS FROM ITS LIBRARY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2114759326","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2114759326","pubTimestamp":1614297042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 25 (Reuters) - ZIOPHARM Oncology Inc   :   * ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Ziopharm肿瘤学报告第4季度和2020年全年财务结果简介","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIOP":0.9},"content_text":"Feb 25 (Reuters) - ZIOPHARM Oncology Inc   :   * ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS   * Q4 LOSS PER SHARE $0.11   * Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA   * HEIDI HAGEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER REPLACING DR. LAURENCE COOPER; SEARCH FOR PERMANENT CEO INITIATED   * NET LOSS FOR Q4 OF 2020, WAS $22.8 MILLION, OR $0.11 PER SHARE   * CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2020 WERE $115.1 MILLION   * CASH POSITION IS SUFFICIENT TO FUND COMPANY OPERATIONS INTO Q2 OF 2022   * RECEIVED IND CLEARANCE BY U.S. FDA FOR CO'S TCR-T TRIAL UTILIZING SIX \"HOTSPOT\" TCRS FROM ITS LIBRARYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}